Why the study?
Endothelial dysfunction plays a prominent role across the cardiovascular continuum and represents a significant therapeutic target, requiring an up-to-date overview of biomarkers and therapeutic correction strategies.
Key points are not available for this paper at this time.
Design
Literature review
May inform risk assessment across the CV continuum but should not yet change practice; leaves open prospective trials of biomarker-guided therapies.
Highlights . The article presents a review of literature data on the diagnostic role of endothelial dysfunction biomarkers. The review provides an overview of the main indicators, their significance in various pathologies, and presents possible therapeutic strategies for preventing endothelial dysfunction. Abstract . Endothelial dysfunction is a characteristic feature of each stage of the cardiovascular continuum – a series of events from hypertension to the development of atherosclerosis and coronary heart disease, thrombus formation, myocardial infarction, and heart failure. Due to the prominent role of endothelial dysfunction in the pathogenesis of many vascular diseases, it is a significant therapeutic target. It is important to note that circulating markers of endothelial activation and damage characterize the severity of the disease and can be used to evaluate the efficacy of treatment and subsequent prognosis. The purpose of this review is to provide up–to-date data on endothelial function, discussing its clinical relevance in the cardiovascular continuum, the latest insights in molecular and cellular biology, and their implications for clinical practice, with a focus on new methods of therapeutic approaches for correcting endothelial dysfunction.
No takes yet. Share an insight, caveat, or question.
Zakharyan et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: